natgillin/translations-raw huggingface dataset:
Det skal besluttes, om amning skal ophøre eller behandling med upadacitinib seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue upadacitinib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Upadacitinib blev administreret i kliniske studier i doser svarende til op til en daglig AUC på 60 mg én gang dagligt (depottabletter).
Upadacitinib was administered in clinical studies up to doses equivalent in daily AUC to 60 mg prolonged-release once daily.
LDA DAS28-CRP ≤ 3,2 (%-del af patienterne)
LDA DAS28-CRP ≤3.2 (% of patients)
• medicin til behandling af svampeinfektioner (f.eks. itraconazol, posaconazol eller voriconazol)
• medicines to treat fungal infections (such as itraconazole, posaconazole or voriconazole)
Dette er vigtigt, fordi nogen typer medicin kan forringe virkningen af RINVOQ eller øge risikoen for bivirkninger.
This is because some medicines may reduce how well RINVOQ works or may increase the risk of getting side effects.
Dyrestudier har vist reproduktionstoksicitet (se punkt 5.3).
Studies in animals have shown reproductive toxicity (see section 5.3).
Lægens informationsmateriale skal indeholde:
The physician educational material should contain:
Upadacitinibs potentielle indvirkning på andre lægemidlers farmakokinetik
Potential for upadacitinib to affect the pharmacokinetics of other medicinal products
Patienten bør screenes for tuberkulose (TB), før behandlingen med upadacitinib iværksættes.
Patients should be screened for tuberculosis (TB) before starting upadacitinib therapy.
De hyppigste alvorlige infektioner, der er indberettet ved anvendelse af upadacitinib, omfatter lungebetændelse og cellulitis (se pkt.
The most frequent serious infections reported with upadacitinib included pneumonia and cellulitis (see section 4.8).
• Et patient kort
• A patient alert card
Det er især vigtigt, at du fortæller det til lægen eller apotekspersonalet, hvis du tager et eller flere af nedenstående lægemidler:
It is very important to talk to your doctor or pharmacist if you are taking any of the following:
Virkningen indtrådte hurtigt for alle mål, idet ACR20-responset var bedre og allerede sås i uge 1.
Time to onset of efficacy was rapid across measures with greater responses seen as early as week 1 for ACR20.
Patienterne bør overvåges for udvikling af tegn og symptomer på TB, også patienter, der er testet negative for latent TB-infektion, inden iværksættelse af behandlingen.
Patients should be monitored for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.
• hvis du har haft en blodprop i benet (dyb venetrombose) eller lungerne (lungeemboli).
• you have had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism).
Der er ikke fundet aktive upadacitinib-metabolitter.
No active metabolites have been identified for upadacitinib.
• Filmovertræk: polyvinylalkohol, macrogol, talcum, titandioxid, rød jernoxid (E172), sort jernoxid (E172).
• Film coating: poly(vinyl alcohol), macrogol, talc, titanium dioxide, iron oxide red (E172), iron oxide black (E172).
CDAI ≤ 10 (%-del af patienterne)
CDAI ≤10 (% of patients)
Nedsat nyrefunktion har ingen klinisk relevant betydning for upadacitinibs eksponering.
Renal impairment has no clinically relevant effect on upadacitinib exposure.
Virus-reaktivering
Viral reactivation
Anti-TB-behandling bør overvejes inden påbegyndelse af upadacitinib hos patienter med tidligere ubehandlet latent TB eller patienter med risikofaktorer for TB-infektion.
Anti-TB therapy should be considered prior to initiation of upadacitinib in patients with previously untreated latent TB or in patients with risk factors for TB infection.
RINVOQ anvendes til behandling af voksne med leddegigt (reumatoid artritis).
RINVOQ is used to treat adults with rheumatoid arthritis.
• medicin til behandling af Cushings syndrom (f.eks. ketoconazol)
• medicines to treat Cushing's syndrome (such as ketoconazole)
Sími: +40 21 529 30 35
Tel: +40 21 529 30 35
Behandlingen med upadacitinib bør genoptages, når infektionen er under kontrol.
Upadacitinib therapy may be resumed once the infection is controlled.
Upadacitinib var ikke mutagent eller genotoksisk i henhold til resultaterne af in vitro- og in vivo-test for genmutationer og kromosomafvigelser.
Upadacitinib was not mutagenic or genotoxic based on the results of in vitro and in vivo tests for gene mutations and chromosomal aberrations.
• hvis du har haft hepatitis B eller C (leverbetændelse)
• you have ever had hepatitis B or C
Risici og fordele ved upadacitinib bør overvejes, inden der iværksættes behandling hos patienter med en kendt malignitet (gælder ikke en velbehandlet non-melanom hudkræft (NMSC)), eller inden upadacitinib-behandling fortsættes hos patienter, der har udviklet en malignitet.
The risks and benefits of upadacitinib treatment should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing upadacitinib therapy in patients who develop a malignancy.
Det er for at tjekke, om du har lavt antal røde blodlegemer (anæmi), lavt antal hvide blodlegemer (neutropeni eller lymfopeni), forhøjet kolesterol (fedtstof) i blodet eller forhøjede leverenzymer.
This is to check for a low red blood cell count (anaemia), low white blood cell count (neutropaenia or lymphopaenia), high blood fat (cholesterol) or high levels of liver enzymes.
Upadacitinibs plasmaeksponering er dosisproportional over det terapeutiske dosisinterval.
Upadacitinib plasma exposures are proportional to dose over the therapeutic dose range.
American College of Rheumatology-kriterierne på ≥ 20 % (eller ≥ 50 %); bDMARD = biologisk sygdomsmodificerende antireumatisk lægemiddel, CRP = C-reaktivt protein, DAS28 = sygdomsaktivitetsscore for 28 led, mTSS = modificeret total Sharp-score, csDMARD = konventionelt syntetisk sygdomsmodificerende antireumatisk lægemiddel, HAQ-DI = Health Assessment Questionnaire Disability Index (spørgeskema til vurdering af helbred og funktionsevne), SF-36 PCS = Short Form (36) Health Survey (SF-36) Physical Component Score, CDAI = klinisk sygdomsaktivitetsindeks, FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue score, UR = utilstrækkelige respondere, MTX = methotrexat, n = antal randomiserede a Patienterne var MTX-naive eller fik højst 3 ugentlige MTX-doser b Patienterne udviste utilstrækkeligt respons på MTX c Patienter, der udviste utilstrækkeligt respons på csDMARD's; patienter, der tidligere var blevet eksponeret for højst ét biologisk DMARD, var egnede (op til 20 % af det samlede antal patienter), hvis de enten var blevet begrænset eksponeret (< 3 måneder) eller var nødt til at seponere det biologisk DMARD på grund af intolerans d Patienter, der udviste utilstrækkeligt respons på MTX; patienter, der tidligere var blevet eksponeret for højst ét bDMARD (bortset fra adalimumab), var egnede (op til 20 % af det samlede antal patienter), hvis de enten var blevet begrænset eksponeret (< 3 måneder) eller var nødt til at seponere det biologiske DMARD på grund af intolerans e Patienter, der udviste utilstrækkeligt respons eller intolerans over for mindst ét biologisk DMARD
bDMARD = biologic disease-modifying anti-rheumatic drug, CRP = C-Reactive Protein, DAS28 = Disease Activity Score 28 joints, mTSS = modified Total Sharp Score, csDMARD = conventional synthetic diseasemodifying anti-rheumatic drug, HAQ-DI = Health Assessment Questionnaire Disability Index, SF-36 PCS = Short Form (36) Health Survey (SF-36) Physical Component Score, CDAI = Clinical Disease Activity Index, FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue score, IR = inadequate responder, MTX = methotrexate, n = number randomised a. Patients were naïve to MTX or received no more than 3 weekly MTX doses b Patients had inadequate response to MTX c Patients who had an inadequate response to csDMARDs; patients with prior exposure to at most one bDMARD were eligible (up to 20% of total number of patients) if they had either limited exposure (<3 months) or had to discontinue the bDMARD due to intolerability d Patients who had an inadequate response to MTX; patients with prior exposure to at most one bDMARD (except adalimumab) were eligible (up to 20% of total study number of patients) if they had either limited exposure (<3 months) or had to discontinue the bDMARD due to intolerability e Patients who had an inadequate response or intolerance to at least one bDMARD
Ved eksponeringer (baseret på AUC) på ca. 4-10 gange den kliniske dosis på 15 mg hos SpragueDawley-rotter af hhv. han- og hunkøn var upadacitinib ikke karcinogent i et 2-årigt karcinogenicitetsstudie .
Upadacitinib, at exposures (based on AUC) approximately 4 and 10 times the clinical dose of 15 mg in male and female Sprague-Dawley rats, respectively, was not carcinogenic in a 2-year carcinogenicity study in Sprague-Dawley rats.
Upadacitinib havde ingen indvirkning på fertiliteten hos han- og hunrotter ved doser på op til 50 mg/kg/dag hos hanrotter og 75 mg/kg/dag hos hunrotter i et studie af fertilitet og tidlig fosterudvikling.
Upadacitinib had no effect on fertility in male or female rats at doses up to 50 mg/kg/day in males and 75 mg/kg/day in females in a fertility and early embryonic development study.
• Tag RINVOQ på samme tidspunkt hver dag, så det er lettere at huske.
• To help you remember to take RINVOQ, take it at the same time every day.
Methotrexat og pH-modificerende lægemidler (f.eks. antacider eller protonpumpehæmmere) har ingen indvirkning på upadacitinibs plasmaeksponering.
Methotrexate and pH modifying medicinal products (e.g., antacids or proton pump inhibitors) have no effect on upadacitinib plasma exposures.
Kvinder, der kan blive gravide, bør have at vide, at de skal bruge sikker prævention under behandlingen og i 4 uger efter den sidste dosis upadacitinib.
Women of childbearing potential should be advised to use effective contraception during treatment and for 4 weeks following the final dose of upadacitinib.
De gennemsnitlige kreatininfosfokinaseværdier steg efter 4 uger, idet der sås en gennemsnitlig stigning på 60 E/l efter 12 uger, hvorefter de forhøjede værdier forblev på et stabilt niveau, også ved længerevarende behandling.
Mean CPK values increased by 4 weeks with a mean increase of 60 U/L at 12 weeks and then remained stable at an increased value thereafter including with extended therapy.
Dyrestudier tyder ikke på skadevirkninger, hvad angår fertiliteten (se pkt.
Animal studies do not indicate effects with respect to fertility (see section 5.3).
Patienter, der testede positive for hepatitis B-overfladeantigen eller hepatitis B-virus DNA, blev ekskluderet fra kliniske studier.
Patients who were positive for hepatitis B surface antigen or hepatitis B virus DNA were excluded from clinical studies.
Hvis du har taget for meget RINVOQ, skal du kontakte lægen.
If you take more RINVOQ than you should, contact your doctor.
Upadacitinib-eksponeringen reduceres ved samtidig administration af stærke CYP3A4-inducere (f.eks. rifampicin og phenytoin), og det kan føre til nedsat terapeutisk effekt af upadacitinib.
Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin and phenytoin), which may lead to reduced therapeutic effect of upadacitinib.
Hvis der ses forhøjet ALAT eller ASAT ved den rutinemæssige patientbehandling, og hvis der er mistanke om lægemiddelinduceret leverskade, bør upadacitinib-behandlingen afbrydes, indtil denne diagnose er udelukket.
If increases in ALT or AST are observed during routine patient management and drug-induced liver injury is suspected, upadacitinib therapy should be interrupted until this diagnosis is excluded.
Overvej alternativer til stærke CYP3A4hæmmere ved længerevarende behandling.
Consider alternatives to strong CYP3A4 inhibitor medications when used in the long-term.
Upadacitinibs farmakokinetik er endnu ikke undersøgt hos en pædiatrisk population (se pkt.
The pharmacokinetics of upadacitinib have not yet been evaluated in a paediatric population (see section 4.2).
• medicin til behandling af bakterieinfektioner (f.eks. clarithromycin)
• medicines to treat bacterial infections (such as clarithromycin)
De hyppigste alvorlige bivirkninger er alvorlige infektioner (se pkt.
The most common serious adverse reactions were serious infections (see section 4.4).
Hvis en patient udvikler herpes zoster, bør det overvejes at afbryde upadacitinib-behandlingen, indtil episoden har fortaget sig.
If a patient develops herpes zoster, interruption of upadacitinib therapy should be considered until the episode resolves.
Pakningsstørrelser og yderligere oplysninger Rinvoq indeholder:
Contents of the pack and other information What RINVOQ contains
I studierne SELECT-MONOTHERAPY, SELECT-NEXT, og SELECT-COMPARE gav behandling med upadacitinib 15 mg en signifikant større bedring, hvad angår den gennemsnitlige varighed af ledstivhed om morgenen, sammenholdt med placebo eller MTX.
In the studies SELECT-MONOTHERAPY, SELECT-NEXT, and SELECT-COMPARE, treatment with upadacitinib 15 mg resulted in a significantly greater improvement in the mean duration of morning joint stiffness compared to placebo or MTX.
Behandling med upadacitinib 15 mg, alene eller i kombination med csDMARD's, resulterede i forbedringer i individuelle ACR-komponenter, herunder antallet af ømme og hævede led, samlede patient- og lægevurderinger, HAQ-DI, smertevurdering og hsCRP.
Treatment with upadacitinib 15 mg, alone or in combination with csDMARDs, resulted in improvements in individual ACR components, including tender and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment and hsCRP.
Tabel 1: Laboratoriemålinger og monitoreringsvejledning Laboratoriemåling
Laboratory measures and monitoring guidance Laboratory measure
• Klinisk remission (DAS28-CRP)
• Clinical remission (DAS28-CRP)
Behandlingsgruppe MTX
Treatment group MTX
Upadacitinib-eksponeringen øges ved samtidig administration af stærke CYP3A4-hæmmere (f.eks. ketoconazol, itraconazol, posaconazol, voriconazol og clarithromycin).
Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, posaconazole, voriconazole, and clarithromycin).
Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, RINVOQ can cause side effects, although not everybody gets them.
Let nedsat leverfunktion (Child-Pugh A) og moderat nedsat leverfunktion (Child-Pugh B) har ingen klinisk relevant betydning for upadacitinibs eksponering.
Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment has no clinically relevant effect on upadacitinib exposure.
Der er set maligniter i kliniske studier med upadacitinib.
Malignancies were observed in clinical studies of upadacitinib.
Forkortelser: ADA = adalimumab; HAQ-DI = Health Assessment Questionnaire Disability Index (spørgeskema til vurdering af helbred og funktionsevne); UR = utilstrækkelige respondere; MTX = methotrexat; PBO = placebo; UPA = upadacitinib a De viste data er gennemsnitsværdier b Health Assessment Questionnaire-Disability Index (spørgeskema til vurdering af helbred og funktionsevne): 0 = bedst, 3 = værst; 20 spørgsmål; 8 kategorier: klæde sig på og soignering, stå op, spise, gå, personlig hygiejne, række ud efter ting, gribe fat om ting og andre aktiviteter.
Abbreviations: ADA = adalimumab; HAQ-DI = Health Assessment Questionnaire Disability Index; IR = inadequate responder; MTX = methotrexate; PBO = placebo; UPA = upadacitinib a Data shown are mean b Health Assessment Questionnaire-Disability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Du skal have taget blodprøver, før du begynder at tage RINVOQ, eller mens du er i behandling.
You will need blood tests before you start taking RINVOQ, or while you are taking it.
RINVOQ anbefales ikke til børn og unge under 18 år, da lægemidlet ikke er undersøgt hos denne aldersgruppe.
RINVOQ is not recommended for use in children and adolescents under 18 years of age.
Sími: +351 (0)21 1908400
Tel: +351 (0)21 1908400
Kalenderblisterpakninger af aluminium (polyvinylchlorid/polyethylen/polychlorotrifluoroethylen) i pakninger med 28 eller 98 depottabletter eller i multipakninger med 84 (3 æsker med 28) depottabletter.
Polyvinylchloride/polyethylene/polychlorotrifluoroethylene - aluminium calendar blisters in packs containing 28 or 98 prolonged-release tablets, or multipacks containing 84 (3 packs of 28) prolongedrelease tablets.
Den anbefalede dosis upadacitinib er 15 mg én gang dagligt.
The recommended dose of upadacitinib is 15 mg once daily.
Upadacitinib påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Upadacitinib has no or negligible influence on the ability to drive and use machines.
Forekomsten af infektionsrelaterede bivirkninger for upadacitinib sammenholdt med placebo var som følger: Infektion i de øvre luftveje (13,5 % vs. 9,5 %), pneumoni (0,5 % vs. 0,3 %), herpes zoster (0,7 % vs. 0,2 %), herpes simplex (0,8 % vs. 0,5 %) og oral candidiasis (0,4 % vs. < 0,1 %).
The frequencies of infection ADRs for upadacitinib compared to placebo were: URTI (13.5% vs 9.5%), pneumonia (0.5% vs 0.3%), herpes zoster (0.7% vs 0.2%), herpes simplex (0.8% v 0.5%), and oral candidiasis (0.4% vs. <0.1%).
RINVOQ 15 mg-depottabletter er lilla, aflange, bikonvekse (udadbuede) tabletter præget med "a15" på den ene side.
RINVOQ 15 mg prolonged-release tablets are purple, oblong, biconvex tablets imprinted on one side with ‘a15'.
Behandling med upadacitinib 15 mg gav signifikant større hæmning af progressionen af strukturelle ledskader sammenholdt med placebo i kombination med MTX i SELECT-COMPARE og som monoterapi sammenholdt med MTX i SELECT-EARLY (tabel 5).
Treatment with upadacitinib 15 mg resulted in significantly greater inhibition of the progression of structural joint damage compared to placebo in combination with MTX in SELECT-COMPARE and as monotherapy compared to MTX in SELECT-EARLY (Table 5).
Upadacitinib bør ikke anvendes under amning.
Upadacitinib should not be used during breast-feeding.
Hvis du ammer eller planlægger at amme, skal du spørge lægen til råds, før du tager dette lægemiddel.
If you are breast-feeding or are planning to breast-feed, talk to your doctor before taking this medicine.
SELECT BEYOND bDMARD-UR
SELECT BEYOND bDMARD-IR
Behandling med upadacitinib 15 mg var forbundet med dosisafhængige forhøjede lipidparametre, herunder total kolesterol, triglycerider, LDL-kolesterol og HDL-kolesterol.
Upadacitinib 15 mg treatment was associated with dose-dependent increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol and HDL cholesterol.
AbbVie UAB Sími: +370 5 205 3023
AbbVie UAB Tel: +370 5 205 3023
AbbVie SIA Sími: +371 67605000
AbbVie SIA Tel: +371 67605000
De hyppigst indberettede bivirkninger er infektioner i de øvre luftveje (13,5 %), kvalme (3,5 %), øget kreatinfosfokinase (CPK) i blodet (2,5 %) og hoste (2,2 %).
The most commonly reported adverse drug reactions (ADRs) are upper respiratory tract infections (13.5%), nausea (3.5%), blood creatine phosphokinase (CPK) increased (2.5%) and cough (2.2%).
Den dosisrelaterede stigning i føtale resorptioner forbundet med postimplantationstab ved 25 og 75 mg/kg/dag i dette studie hos rotter blev tilskrevet upadacitinibs teratogene effekt og dets indvirkning på udviklingen.
Dose related increases in foetal resorptions associated with post-implantation losses at 25 and 75 mg/kg/day in this study in rats were attributed to the developmental/teratogenic effects of upadacitinib.
I studierne opnåede en signifikant højere andel af de patienter, der blev behandlet med upadacitinib 15 mg, lav sygdomsaktivitet (DAS28-CRP ≤ 3,2) og klinisk remission (DAS28-CRP < 2,6) sammenholdt med placebo, MTX eller adalimumab (tabel 4).
In the studies, a significantly higher proportion of patients treated with upadacitinib 15 mg achieved low disease activity (DAS28-CRP ≤3.2) and clinical remission (DAS28-CRP <2.6) compared to placebo, MTX or adalimumab (Table 4).
Kreatininfosfokinase
Creatine phosphokinase
Vægtøgning * Infektion i de øvre luftveje omfatter: akut sinuitis, laryngitis, nasofaryngitis, orofaryngeale smerter, faryngitis, faryngotonsillitis, rhinitis, sinuitis, tonsillitis, virusinfektion i de øvre luftveje ** Herpes simplex omfatter oral herpes
Blood CPK increased ALT increased AST increased Weight increased * URTI includes: acute sinusitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, viral upper respiratory tract infection ** Herpes simplex includes oral herpes
I et klinisk studie faldt AUC for rosuvastatin og atorvastatin hos raske forsøgspersoner med hhv. 33 % og 23 %, og rosuvastatins Cmax faldt med 23 % efter administration af multiple doser upadacitinib på 30 mg én gang dagligt.
In a clinical study, rosuvastatin and atorvastatin AUC were decreased by 33% and 23%, respectively, and rosuvastatin Cmax was decreased by 23% following the administration of multiple 30 mg once daily doses of upadacitinib to healthy subjects.
HDPE-beholdere med tørremiddel og polypropylenlåg i æske med 30 depottabletter.
HDPE bottles with desiccant and polypropylene cap in carton containing 30 prolonged-release tablets.
Hvis der identificeres hepatitis B-virus DNA under behandling med upadacitinib, bør en hepatolog tages med på råd.
If hepatitis B virus DNA is detected while receiving upadacitinib, a liver specialist should be consulted.
• Tabletkerne: mikrokrystallinsk cellulose, mannitol, vinsyre, hypromellose, vandfri kolloid silica, magnesiumstearat.
• Core tablet: microcrystalline cellulose, mannitol, tartaric acid, hypromellose, silica colloidal anhydrous, magnesium stearate.
• Risiko for alvorlige og opportunistiske infektioner, herunder TB o En tekst om risikoen for infektioner under behandling med upadacitinib o Oplysninger om, hvordan man reducerer risikoen for infektion med specifikke kliniske forholdsregler (hvilke laboratorieparametre, der skal bruges til at initiere upadacitinib, screening for TB, immunisering af patienter i henhold til lokale retningslinier og afbrydelse af upadacitinib, hvis der udvikles en infektion) o En tekst om at undgå levende vacciner (dvs. Zostavax) før og under upadacitinibbehandling o Oplysninger for at rådgive patienter om tegn/symptomer på infektion og at være opmærksom på dette, så patienterne hurtigt kan søge lægehjælp.
• Risk of serious and opportunistic infections including TB o Language on the risk of infections during treatment with upadacitinib o Details on how to reduce the risk of infection with specific clinical measures (what laboratory parameters should be used to initiate upadacitinib, screening for TB, and getting patients immunised as per local guidelines, and interruption of upadacitinib if an infection develops) o Language on avoidance of live vaccines (i.e., Zostavax) prior to and during upadacitinib treatment o Details to advise patients on signs/symptoms of infection to be aware of, so that patients can seek medical attention quickly.
Det skal du vide, før du begynder at tage RINVOQ 3.
What you need to know before you take RINVOQ 3.
Upadacitinib bør ikke gives til patienter med aktiv TB (se pkt.
Upadacitinib should not be given to patients with active TB (see section 4.3).
I alle studier havde flere upadacitinib 15 mg-behandlede patienter opnået ACR20-, ACR50- og ACR70-respons efter 12 uger sammenholdt med placebo, MTX eller adalimumab (tabel 4).
In all studies, more patients treated with upadacitinib 15 mg achieved ACR20, ACR50, and ACR70 responses at 12 weeks compared to placebo, MTX, or adalimumab (Table 4).
• medicin til behandling af tuberkulose (f.eks. rifampicin)
• medicines to treat tuberculosis (such as rifampicin)